Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

AbbVie Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

AbbVie Inc., consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net earnings
Depreciation
Amortization of intangible assets
Deferred income taxes
Change in fair value of contingent consideration liabilities
Payments of contingent consideration liabilities
Stock-based compensation
Acquired IPR&D and milestones
Other charges related to collaborations
Gain on divestitures
Non-cash litigation reserve adjustments, net of cash payments
Impairment of intangible assets
Other, net
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable and other liabilities
Income tax assets and liabilities, net
Changes in operating assets and liabilities, net of acquisitions
Adjustments to reconcile net earnings to net cash from operating activities
Cash flows from operating activities
Acquisition of businesses, net of cash acquired
Other acquisitions and investments
Acquisitions of property and equipment
Purchases of investment securities
Sales and maturities of investment securities
Other, net
Cash flows from investing activities
Net change in commercial paper borrowings
Repayments of other short-term borrowings
Proceeds from issuance of long-term debt
Repayments of long-term debt and finance lease obligations
Debt issuance costs
Dividends paid
Purchases of treasury stock
Proceeds from the exercise of stock options
Payments of contingent consideration liabilities
Other, net
Cash flows from financing activities
Effect of exchange rate changes on cash and equivalents
Net change in cash and equivalents
Cash and equivalents, beginning of year
Cash and equivalents, end of year

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Cash flow statement item Description The company
Cash flows from operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. AbbVie Inc. cash flows from operating activities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Cash flows from investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. AbbVie Inc. cash flows from investing activities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Cash flows from financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. AbbVie Inc. cash flows from financing activities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.